A detailed history of Black Rock Inc. transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 3,135,115 shares of TRVI stock, worth $12.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,135,115
Previous 2,375,709 31.97%
Holding current value
$12.7 Million
Previous $8.2 Million 13.98%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$2.44 - $3.36 $1.85 Million - $2.55 Million
759,406 Added 31.97%
3,135,115 $9.34 Million
Q1 2024

May 10, 2024

BUY
$1.3 - $3.7 $72,790 - $207,174
55,993 Added 2.41%
2,375,709 $8.2 Million
Q4 2023

Feb 13, 2024

BUY
$1.06 - $2.05 $181,740 - $351,478
171,453 Added 7.98%
2,319,716 $3.11 Million
Q3 2023

Nov 13, 2023

SELL
$2.11 - $2.47 $182,721 - $213,897
-86,598 Reduced 3.87%
2,148,263 $4.68 Million
Q2 2023

Aug 11, 2023

BUY
$1.8 - $3.44 $3.87 Million - $7.4 Million
2,152,616 Added 2617.32%
2,234,861 $5.34 Million
Q1 2023

May 12, 2023

BUY
$1.69 - $2.97 $2,491 - $4,377
1,474 Added 1.82%
82,245 $152,000
Q4 2022

Feb 13, 2023

BUY
$1.61 - $2.42 $35,334 - $53,111
21,947 Added 37.31%
80,771 $155,000
Q3 2022

Nov 14, 2022

BUY
$1.54 - $4.28 $2,048 - $5,692
1,330 Added 2.31%
58,824 $90,000
Q2 2022

Aug 12, 2022

BUY
$1.8 - $3.39 $43,299 - $81,546
24,055 Added 71.94%
57,494 $161,000
Q1 2022

May 12, 2022

SELL
$0.46 - $2.48 $5,294 - $28,542
-11,509 Reduced 25.61%
33,439 $73,000
Q4 2021

Feb 10, 2022

BUY
$0.68 - $1.5 $713 - $1,573
1,049 Added 2.39%
44,948 $35,000
Q3 2021

Nov 09, 2021

SELL
$1.29 - $2.18 $362 - $612
-281 Reduced 0.64%
43,899 $61,000
Q2 2021

Aug 11, 2021

BUY
$2.0 - $2.76 $88,360 - $121,936
44,180 New
44,180 $99,000

Others Institutions Holding TRVI

About Trevi Therapeutics, Inc.


  • Ticker TRVI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,322,500
  • Market Cap $237M
  • Description
  • Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...
More about TRVI
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.